Brain Scans Reveal Dopamine Damage as Possible Cause of Long COVID Fatigue

Brain scans link long COVID fatigue to dopamine neuron damage

Scientists have used advanced neuroimaging to identify a potential source of the crippling fatigue and cognitive slowdown that many people experience after a COVID‑19 infection. The scans show reduced activity in brain regions that release dopamine, a neurotransmitter essential for motivation, movement and memory. This finding could reshape how doctors treat the lingering symptoms that define long COVID.

How the study was conducted

Researchers recruited a cohort of individuals who had recovered from the acute phase of COVID‑19 but continued to report severe fatigue, brain fog and reduced exercise tolerance. Using positron emission tomography (PET) combined with a radioligand that binds to dopamine transporters, the team measured the density of dopamine‑releasing neurons in several brain areas, including the striatum and prefrontal cortex. The results were compared with a control group of healthy volunteers matched for age and sex.

The study, published in a peer‑reviewed journal, found a statistically significant decline in dopamine transporter binding in the long COVID group. The authors noted that the pattern of loss resembled that seen in early Parkinson’s disease, although the clinical presentation differed markedly.

What dopamine does in the brain

Dopamine plays a central role in the brain’s reward and motivation circuits. It helps regulate voluntary movement, attention, learning and the ability to experience pleasure. When dopamine levels fall, people often feel sluggish, lose interest in activities, and struggle with short‑term memory.

Because dopamine pathways intersect with the brain’s arousal system, a deficit can also manifest as a generalized sense of mental fog. This aligns with the most common complaints of long COVID patients, who describe a “brain that feels heavy” and an inability to sustain mental effort.

Symptoms that match dopamine loss

Fatigue and low motivation

Persistent tiredness that does not improve with rest is a hallmark of long COVID. Dopamine deficiency reduces the drive to initiate tasks, making ordinary activities feel exhausting. Patients often report a lack of enthusiasm for hobbies they once enjoyed, a symptom that mirrors clinical observations in conditions such as depression and chronic fatigue syndrome.

Slowed movement and memory lapses

In addition to mental fatigue, many sufferers notice subtle changes in motor function. Simple actions like climbing stairs or typing may require extra effort. Memory problems, especially difficulty recalling recent conversations or details, are also frequently reported. Both issues are consistent with impaired dopamine signaling in the basal ganglia and prefrontal cortex.

Potential treatment pathways

Existing drugs that boost dopamine

Pharmacological agents that increase dopamine availability are already used for Parkinson’s disease and certain mood disorders. These include levodopa, dopamine agonists such as pramipexole, and drugs that inhibit dopamine reuptake. Early case reports suggest that a carefully monitored trial of these medications could alleviate some long COVID symptoms, but large‑scale studies are still needed.

Ongoing clinical trials

Several research groups have launched trials to test whether dopamine‑targeted therapies can improve fatigue and cognition in long COVID patients. One trial, registered on ClinicalTrials.gov, is evaluating the safety of a low‑dose dopamine agonist over a twelve‑week period. Results are expected later this year and could provide the first evidence‑based guidance for clinicians.

What patients and clinicians can do now

While definitive treatments are pending, there are practical steps that may help manage symptoms linked to dopamine deficiency.

• Engage in regular, moderate exercise. Physical activity naturally raises dopamine levels and improves mood.
• Prioritize sleep hygiene. Quality sleep supports neurotransmitter balance.
• Consume a diet rich in tyrosine, an amino acid precursor to dopamine. Foods such as lean poultry, dairy, nuts and legumes are good sources.
• Consider cognitive‑behavioral strategies that encourage goal setting and reward‑based reinforcement.
• Discuss with a healthcare provider the possibility of a dopamine‑focused medication trial, especially if symptoms are severe.

Healthcare professionals should remain vigilant for signs of dopamine‑related impairment in long COVID patients. Incorporating a brief neurological assessment, such as a finger‑tapping test or a simple memory recall task, can help identify those who may benefit from targeted therapy.

Long COVID remains a complex, multi‑system condition, but the emerging link between dopamine neuron loss and the most disabling symptoms offers a tangible target for research and treatment. As more data become available, patients and clinicians alike can look forward to more precise interventions that address the root cause rather than just the symptoms.

For a broader overview of long COVID symptoms, see the CDC long COVID overview. Detailed information about dopamine’s role in the brain is provided by NIH research on dopamine. The imaging findings were reported in a Nature study on brain imaging in long COVID. The World Health Organization fact sheet provides global statistics, and the Oxford brain science research offers insights into neurochemical pathways.